Form 4: Theravance Biopharma CFO Aziz Sawaf Reports Acquisition of 75,000 Shares
SEC Form 4
Aziz Sawaf, CFO of Theravance Biopharma, reports acquiring 75,000 ordinary shares on February 28, 2025.
Summary
- On February 28, 2025, Aziz Sawaf, the SVP & Chief Financial Officer of Theravance Biopharma, Inc. acquired 75,000 ordinary shares of the company.
- The shares were acquired at a price of $0.
- Following the transaction, Sawaf directly owns 374,138 ordinary shares of Theravance Biopharma, Inc.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard SEC filing indicating a transaction by an insider. The acquisition of shares by the CFO could be interpreted as a positive signal, but without additional context, it's difficult to gauge the overall impact.
Positives
- The acquisition of shares by a company executive can be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the trading activities of company insiders, which can influence investor sentiment.
Stakeholder Impact
- The acquisition of shares by a company executive can influence investor sentiment.
Key Dates
| Date | Description |
|---|---|
| 02/28/2025 | Date of transaction: Aziz Sawaf acquired 75,000 ordinary shares. |
| 03/04/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.